Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Not yet recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Multiple Myeloma 26Leukemia, Myeloid, Acute 24Recurrence 12Sarcoma 7Lymphoma, Large B-Cell, Diffuse 6Neoplasm Metastasis 5Neurofibrosarcoma 4Neoplasms, Plasma Cell 4Lymphoma 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Thymoma 2Rhabdoid Tumor 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Melanoma 2Lymphoma, Mantle-Cell 2Liposarcoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Leukemia 2Congenital Abnormalities 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Breast Neoplasms 2Wilms Tumor 1

Interventions

fludarabine phosphate 26Etoposide 23Peripheral Blood Stem Cell Transplantation 22pegaspargase 21Whole-Body Irradiation 21Mycophenolic Acid 20Cyclophosphamide 19Busulfan 17Gemcitabine 16Dexamethasone 16Tacrolimus 15Methotrexate 15Cyclosporine 12Radiotherapy 11Antilymphocyte Serum 11Melphalan 8Asparaginase 8Rituximab 7Oxaliplatin 7Flow Cytometry 6Therapeutics 5Lenalidomide 5Bortezomib 5thymoglobulin 4spartalizumab 4Transplantation 4Polymerase Chain Reaction 4Panobinostat 4Methylprednisolone 4Everolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Extranodal NK-T-Cell × selinexor × Clear all
NCT07554482 2026-04-28

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Beijing Tongren Hospital

Phase 2 Not yet recruiting
34 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT07276698 2025-12-11

Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Not yet recruiting
39 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT06573138 2024-08-27

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Ruijin Hospital

Phase 2 Not yet recruiting
18 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡